adalimumab (preferred products) — Highmark
Crohn’s Disease (CD)
Initial criteria
- age ≥ 6 years
- diagnosis of moderate to severe CD
- prescribed by or in consultation with a gastroenterologist
Reauthorization criteria
- member has demonstrated disease stability or a beneficial response to therapy